BioMarin's early data restores faith in real PARP inhibitors
This article was originally published in Scrip
Early Phase I/II trial data has restored hope that PARP inhibitors may be effective in treating cancer. The PARP inhibitor class took a hit from the failure of Sanofi's iniparib triple-negative breast cancer, but that molecule turned out not to be a PARP inhibitor at all. Now, according to data revealed at the European Cancer Congress (ECC) in Amsterdam on 29 September, around half of the heavily pretreated patients receiving Biomarin's BMN-673 demonstrated an objective response. BioMarin will begin a pivotal Phase III trial to determine the role of BMN-673 in the treatment of BRCA mutation-positive patients. The drug could become the first PARP inhibitor to gain approval for BRCA mutation-positive metastatic breast cancer.
You may also be interested in...
Is multiple myeloma treatment at a tipping point? With new treatment approaches based on monoclonal antibodies and immuno-oncology drug combinations demonstrating improved outcomes, experts hope that the answer may be yes.
Three projects that will drive future growth were highlighted at Bayer's Perspective on Innovation 2014 Meeting, held in Leverkusen on 2 December 2014. The company singled out the protein free formulation of its blockbuster hemophilia A therapy Kogenate (BAY 81-8973), regorafenib eye drops for wet age-related macular degeneration, and the androgen receptor inhibitor ODM-201, which is partnered with Orion.
With an FDA panel unanimously recommending accelerated approval for Adcetris for relapsed/refractory Hodgkin's lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma - and with treatment options for these indications limited - commercial success for the drug could attract further investment in antibody-drug conjugate (ADC) technologies.